Osimertinib Recruiting Phase 1 Trials for Metastatic Non-Small Cell Lung Cancer Treatment

IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT03810807Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer